Glucotrack Raises About $4M in Stock Deal of 1.03M Shares Priced at $3.87 Per Share

Glucotrack, Inc. (NASDAQ:GCTK) (the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 1,033,591 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,067,182 shares of common stock at an effective combined price of $3.87 per share and common warrant for aggregate gross proceeds of approximately $4.0 million, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $3.87 per share, will not be exercisable until receipt of shareholder approval and will expire five years from the initial exercise date.

The closing of the offering is expected to occur on or about December 31, 2025, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering for working capital and general corporate purposes.